- Home
- SIM vs AKRO Comparison
SIM vs AKRO Comparison
Compare SIM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIM
- AKRO
- Stock Information
- Founded
- SIM 1969
- AKRO 2017
- Country
- SIM Mexico
- AKRO United States
- Employees
- SIM N/A
- AKRO N/A
- Industry
- SIM Steel/Iron Ore
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SIM Industrials
- AKRO Health Care
- Exchange
- SIM Nasdaq
- AKRO Nasdaq
- Market Cap
- SIM 4.1B
- AKRO 4.5B
- IPO Year
- SIM 1993
- AKRO 2019
- Fundamental
- Price
- SIM $29.89
- AKRO $54.29
- Analyst Decision
- SIM
- AKRO Buy
- Analyst Count
- SIM 0
- AKRO 10
- Target Price
- SIM N/A
- AKRO $73.56
- AVG Volume (30 Days)
- SIM 1.4K
- AKRO 1.7M
- Earning Date
- SIM 10-27-2025
- AKRO 11-07-2025
- Dividend Yield
- SIM N/A
- AKRO N/A
- EPS Growth
- SIM N/A
- AKRO N/A
- EPS
- SIM 0.94
- AKRO N/A
- Revenue
- SIM $1,698,258,820.00
- AKRO N/A
- Revenue This Year
- SIM N/A
- AKRO N/A
- Revenue Next Year
- SIM N/A
- AKRO N/A
- P/E Ratio
- SIM $31.92
- AKRO N/A
- Revenue Growth
- SIM N/A
- AKRO N/A
- 52 Week Low
- SIM $22.15
- AKRO $21.34
- 52 Week High
- SIM $34.48
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- SIM 62.20
- AKRO 68.62
- Support Level
- SIM $28.10
- AKRO $54.10
- Resistance Level
- SIM $30.00
- AKRO $54.37
- Average True Range (ATR)
- SIM 0.97
- AKRO 0.19
- MACD
- SIM 0.24
- AKRO -0.23
- Stochastic Oscillator
- SIM 38.24
- AKRO 87.74
About SIM Grupo Simec S.A.B. de C.V.
Grupo Simec SAB de CV is a diversified producer, processor and distributor of SBQ steel and structural steel products with production and commercial operations. The group's SBQ products are used across a range of engineered end-user applications, including axles, hubs, and crankshafts for automobiles and light trucks, machine tools, and off-highway equipment. Its structural steel products are used in the non-residential construction market and other construction applications. Its segments are Mexico, Brazil, and the United States. The maximum of its sales is from the Mexico segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.